Literature DB >> 17306963

An fMRI study of language processing in people at high genetic risk for schizophrenia.

Xiaobo Li1, Craig A Branch, Hilary C Bertisch, Kyle Brown, Kamila U Szulc, Babak A Ardekani, Lynn E DeLisi.   

Abstract

BACKGROUND: Abnormalities in language processing and the related brain structures have been reported in people with schizophrenia. It has been proposed that the brain pathways for language processing are anomalous in these individuals and form the underlying basis for the positive symptoms of the illness. If language pathway abnormalities can be detected early in people at high-risk for schizophrenia prior to the onset of symptoms, early treatment can ensue.
METHODS: Fifteen young adults at high genetic risk for developing schizophrenia were compared with 15 of their siblings with schizophrenia or schizoaffective disorder and 15 age and sex matched individuals at low risk for schizophrenia using a visual lexical decision task during fMRI. The data were analyzed by contrasting activation obtained during a real word-pseudoword discrimination task to activation obtained during a nonlinguistic discrimination task, and the differential activations were examined.
RESULTS: Patterns of brain activation while reading and discriminating between real and pseudowords differed across groups, with more bilateral activation in schizophrenia patients and their high-risk siblings than controls. In control subjects discrimination of words from psuedowords significantly activated Brodmann's area 44 more strongly than when non-linguistic symbols were discriminated. However, high-risk subjects and their siblings with schizophrenia activated this region similarly for both language and non-language tasks.
CONCLUSIONS: Normal individuals can be distinguished from subjects at high genetic risk for schizophrenia and patients with schizophrenia by their more lateralized and stronger activation of Brodmann's area 44 to word compared with symbol discrimination tasks. Thus, evaluation of language processing by fMRI may be a valuable tool for use in the prediction of individual risk for developing schizophrenia.

Entities:  

Mesh:

Year:  2007        PMID: 17306963      PMCID: PMC1978181          DOI: 10.1016/j.schres.2006.12.016

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  40 in total

Review 1.  The significance of age of onset for schizophrenia.

Authors:  L E DeLisi
Journal:  Schizophr Bull       Date:  1992       Impact factor: 9.306

2.  A three-dimensional statistical analysis for CBF activation studies in human brain.

Authors:  K J Worsley; A C Evans; S Marrett; P Neelin
Journal:  J Cereb Blood Flow Metab       Date:  1992-11       Impact factor: 6.200

3.  Multilevel linear modelling for FMRI group analysis using Bayesian inference.

Authors:  Mark W Woolrich; Timothy E J Behrens; Christian F Beckmann; Mark Jenkinson; Stephen M Smith
Journal:  Neuroimage       Date:  2004-04       Impact factor: 6.556

4.  Functional magnetic resonance imaging during auditory verbal working memory in nonpsychotic relatives of persons with schizophrenia: a pilot study.

Authors:  Heidi W Thermenos; Larry J Seidman; Hans Breiter; Jill M Goldstein; Julie M Goodman; Russell Poldrack; Stephen V Faraone; Ming T Tsuang
Journal:  Biol Psychiatry       Date:  2004-03-01       Impact factor: 13.382

5.  Genetic load on amygdala hypofunction during sadness in nonaffected brothers of schizophrenia patients.

Authors:  Ute Habel; Martina Klein; N Jon Shah; Ivan Toni; Karl Zilles; Peter Falkai; Frank Schneider
Journal:  Am J Psychiatry       Date:  2004-10       Impact factor: 18.112

6.  An fMRI study of semantic processing in men with schizophrenia.

Authors:  M Kubicki; R W McCarley; P G Nestor; T Huh; R Kikinis; M E Shenton; C G Wible
Journal:  Neuroimage       Date:  2003-12       Impact factor: 6.556

7.  Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative.

Authors:  J I Nurnberger; M C Blehar; C A Kaufmann; C York-Cooler; S G Simpson; J Harkavy-Friedman; J B Severe; D Malaspina; T Reich
Journal:  Arch Gen Psychiatry       Date:  1994-11

8.  Familial thyroid disease and delayed language development in first admission patients with schizophrenia.

Authors:  L E DeLisi; A M Boccio; H Riordan; A L Hoff; A Dorfman; J McClelland; M Kushner; O Van Eyl; N Oden
Journal:  Psychiatry Res       Date:  1991-07       Impact factor: 3.222

9.  Language activation in monozygotic twins discordant for schizophrenia.

Authors:  Iris E C Sommer; Nick F Ramsey; René C W Mandl; Clarine J van Oel; Renée S Kahn
Journal:  Br J Psychiatry       Date:  2004-02       Impact factor: 9.319

10.  fMRI correlates of state and trait effects in subjects at genetically enhanced risk of schizophrenia.

Authors:  H C Whalley; E Simonotto; S Flett; I Marshall; K P Ebmeier; D G C Owens; N H Goddard; E C Johnstone; S M Lawrie
Journal:  Brain       Date:  2004-01-28       Impact factor: 13.501

View more
  23 in total

1.  Genetic variation in G72 correlates with brain activation in the right middle temporal gyrus in a verbal fluency task in healthy individuals.

Authors:  Axel Krug; Valentin Markov; Sören Krach; Andreas Jansen; Klaus Zerres; Thomas Eggermann; Tony Stöcker; N Jon Shah; Markus M Nöthen; Alexander Georgi; Jana Strohmaier; Marcella Rietschel; Tilo Kircher
Journal:  Hum Brain Mapp       Date:  2011-01       Impact factor: 5.038

Review 2.  The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia.

Authors:  Lynn E DeLisi
Journal:  Schizophr Bull       Date:  2008-02-08       Impact factor: 9.306

Review 3.  Imaging genetic liability to schizophrenia: systematic review of FMRI studies of patients' nonpsychotic relatives.

Authors:  Angus W MacDonald; Heidi W Thermenos; Deanna M Barch; Larry J Seidman
Journal:  Schizophr Bull       Date:  2008-06-12       Impact factor: 9.306

4.  Altered language network activity in young people at familial high-risk for schizophrenia.

Authors:  H W Thermenos; S Whitfield-Gabrieli; L J Seidman; G Kuperberg; R J Juelich; S Divatia; C Riley; G A Jabbar; M E Shenton; M Kubicki; T Manschreck; M S Keshavan; L E DeLisi
Journal:  Schizophr Res       Date:  2013-10-28       Impact factor: 4.939

Review 5.  Diffusion tensor imaging in first degree relatives of schizophrenia and bipolar disorder patients.

Authors:  Hidayet E Arat; Virginie-Anne Chouinard; Bruce M Cohen; Kathryn E Lewandowski; Dost Öngür
Journal:  Schizophr Res       Date:  2014-12-24       Impact factor: 4.939

6.  Decreased axial diffusivity within language connections: a possible biomarker of schizophrenia risk.

Authors:  M Kubicki; M E Shenton; P K Maciejewski; P E Pelavin; K J Hawley; T Ballinger; T Swisher; G A Jabbar; H W Thermenos; M S Keshavan; L J Seidman; L E Delisi
Journal:  Schizophr Res       Date:  2013-06-22       Impact factor: 4.939

7.  An automated method to analyze language use in patients with schizophrenia and their first-degree relatives.

Authors:  Brita Elvevåg; Peter W Foltz; Mark Rosenstein; Lynn E Delisi
Journal:  J Neurolinguistics       Date:  2010-05-01       Impact factor: 1.710

8.  Subcortical structure alterations impact language processing in individuals with schizophrenia and those at high genetic risk.

Authors:  Xiaobo Li; Margaret Black; Shugao Xia; Chenyang Zhan; Hilary C Bertisch; Craig A Branch; Lynn E DeLisi
Journal:  Schizophr Res       Date:  2015-09-18       Impact factor: 4.939

9.  fMRI study of language activation in schizophrenia, schizoaffective disorder and in individuals genetically at high risk.

Authors:  Xiaobo Li; Craig A Branch; Babak A Ardekani; Hilary Bertisch; Chindo Hicks; Lynn E DeLisi
Journal:  Schizophr Res       Date:  2007-08-24       Impact factor: 4.939

10.  Chronic smoking and the BOLD response to a visual activation task and a breath hold task in patients with schizophrenia and healthy controls.

Authors:  Lee Friedman; Jessica A Turner; Hal Stern; Daniel H Mathalon; Liv C Trondsen; Steven G Potkin
Journal:  Neuroimage       Date:  2008-01-05       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.